BMRN BioMarin Pharmaceutical Inc

🔔Trading Update🔔 📅Wednesday 25/01/2023📅 🟢Bullish Activity🟢 $LRN Shares are gapping up above the 200 day SMA this morning after the technology-based education company reported fiscal Q2 earnings of $1.19 per share $0.15 beat on revenue that rose 11.9% YOY to $458.44M above the $443.23M consensus. The company said that Q3 revenue is expected to come in a range of $445-465M above the $437.53M consensus and guided full-year 2023 revenue to a range of $1.775-1.815B above the $1.74B consensus and prior guidance of $1.71-1.79B. The February 17th 45.00 call being the highest volume contract. $T Also to the upside after the telecom giant reported Q4 earnings of $0.61 per share $0.03 beat on revenue that fell 23.6% YOY to $31.3B slightly below the $31.5B consensus as the company added 656K postpaid phone net subscriber additions. The company issued downside guidance as full year 2023 EPS is expected to come in a range of $2.35-2.45 below the $2.56 consensus with FY23 wireless service r

🔔Mid Day Trading Update🔔 📅Monday 28/11/2022📅 🟢Bullish Activity🟢 $AXSM Gapping up to a 52 week high this morning after the biopharmaceutical company announced that its experimental Alzheimer’s drug AXS-05 met the primary and key secondary endpoints in the Assessing Clinical Outcomes in Alzheimer’s Disease Agitation Phase 3 trial. AXS-05 substantially and statistically significantly delayed the time to relapse a 3.6-fold lower risk and prevented relapse of agitation in patients with Alzheimer’s disease as compared to the placebo. The December 16th 100.00 call being the highest volume contract. $BUD Also to the upside after JP Morgan double upgraded the alcoholic beverage maker to Overweight from Underweight and lifted their price target on the stock to $70.00 from $45.00. Analyst Jared Dinges said that he now sees the potential for earnings outperformance and believes the rapid deleveraging of the company’s balance sheet will provide optionality. The December 16th 60.00 call be